Agn-PC-0mvqjv | 477594-30-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Agn-PC-0mvqjv
• 英文别名: N-(2-cyclohexyloxy-3-nitrophenyl)methanesulfonamide
• CAS: 477594-30-2
• 化学式: C13H18N2O5S
• 分子量: 314.36
• InChiKey: YBCBOXOAJAQPQU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  110
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• NOVEL INDOLE DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES
  申请人：Merck Patent GmbH

  公开号：US20160168090A1

  公开（公告）日：2016-06-16

  The present invention relates to indole compounds, and pharmaceutically acceptable compositions thereof, useful as antagonists of P2X7, and for the treatment of P2X7-related disorders.

  本发明涉及吲哚化合物及其药用可接受的组合物，用作P2X7拮抗剂，用于治疗与P2X7相关的疾病。
• Tricyclic delta-opioid modulators
  申请人：Carson R. John

  公开号：US20060135522A1

  公开（公告）日：2006-06-22

  The invention is directed to delta opioid receptor modulators. More specifically, the invention relates to tricyclic δ-opioid modulators. Pharmaceutical and veterinary compositions and methods of treating mild to severe pain and various diseases using compounds of the invention are also described.

  这项发明涉及δ阿片受体调节剂。更具体地，该发明涉及三环δ-阿片调节剂。还描述了利用该发明的化合物治疗轻度至严重疼痛和各种疾病的药用和兽医组合物以及治疗方法。
• [EN] NOVEL P2X7R ANTAGONISTS AND THEIR USE<br/>[FR] NOUVEAUX ANTAGONISTES P2X7R ET LEUR UTILISATION
  申请人：AFFECTIS PHARMACEUTICALS AG

  公开号：WO2012110190A1

  公开（公告）日：2012-08-23

  The present application is directed to novel P2X7R antagonists that are N-indol-3-yl-acetamide and N-azaindol-3-yl-acetamide compounds, pharmaceutical compositions comprising the same and their use for the prophylactic or therapeutic treatment of diseases mediated by P2X7R activity.

  本申请涉及新颖的P2X7R拮抗剂，它们是N-吲哚-3-基乙酰胺和N-氮杂吲哚-3-基乙酰胺化合物，包括这些化合物的药物组合物，以及它们用于预防或治疗由P2X7R活性介导的疾病。
• [EN] INDOLIZINE DERIVATIVES WHICH ARE APPLICABLE TO NEURODEGENERATIVE DISEASES<br/>[FR] DÉRIVÉS D'INDOLIZINE POUVANT ÊTRE EMPLOYÉS DANS DES MALADIES NEURODÉGÉNÉRATIVES
  申请人：MERCK PATENT GMBH

  公开号：WO2016019228A1

  公开（公告）日：2016-02-04

  The present invention relates to indolizine compounds, and pharmaceutically acceptable compositions thereof, useful as antagonists of P2X7, and for the treatment of P2X7-related disorders.

  本发明涉及吲哚啉化合物及其药学上可接受的组合物，用作P2X7拮抗剂，用于治疗与P2X7相关的疾病。
• [EN] NOVEL QUINOLINE DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES<br/>[FR] NOUVEAUX DÉRIVÉS DE QUINOLÉINE ET LEUR UTILISATION DANS DES MALADIES NEURODÉGÉNÉRATIVES
  申请人：MERCK PATENT GMBH

  公开号：WO2015187905A1

  公开（公告）日：2015-12-10

  The present invention relates to quinoline compounds, and pharmaceutically acceptable compositions thereof, useful as antagonists of P2X7, and for the treatment of P2X7-related disorders.

  本发明涉及喹啉化合物及其药用可接受的组合物，用作P2X7的拮抗剂，用于治疗与P2X7相关的疾病。